Alzheimer's Disease
Prevalence: ~50 million worldwide, projected 150 million by 2050
The most common neurodegenerative disease, characterized by progressive memory loss, cognitive decline, and amyloid-beta plaque accumulation. Genetic factors account for 60-80% of risk, with APOE4 being the strongest common risk allele.
Peptide Therapeutics
Anti-amyloid peptides (amyloid-beta aggregation inhibitors), tau-targeting peptides, APOE-modulating peptides (4F, CS6253), and neuroprotective peptides crossing the blood-brain barrier are under active development.
Current Treatments
Lecanemab (anti-amyloid antibody), aducanumab, cholinesterase inhibitors (donepezil, rivastigmine), memantine. No disease-modifying peptide therapeutics approved yet.
Key Genetic Variants
Associated Genes
Lipid transport, cholesterol metabolism, neuronal repair, and amyloid-beta clearance in the brain. APOE is the major genetic risk modulator for late-onset Alzheimer's disease.
Explore peptide candidates for Alzheimer's Disease
Submit rs429358, rs7412 to PepFold. Full report with 3D structures and synthesis protocols in under 2 minutes.